作者
Pierre Tattevin, Erwan Flécher, Vincent Auffret, Christophe Leclercq, Stéphane Boulé, André Vincentelli, Camille Dambrin, Clément Delmas, Laurent Barandon, Vincent Veniard, Michel Kindo, Thomas Cardi, Philippe Gaudard, Philippe Rouvière, Thomas Sénage, Nicolas Jacob, Pascal Defaye, Olivier Chavanon, Constance Verdonk, Marylou Para, Edeline Pelcé, Vlad Gariboldi, Matteo Pozzi, Daniel Grinberg, Arnaud Savouré, Pierre-Yves Litzler, Gerard Babatasi, Annette Belin, Fabien Garnier, Marie Bielefeld, David Hamon, Nicolas Lellouche, Louis Bernard, Thierry Bourguignon, Romain Eschalier, Nicolas d'Ostrevy, Jérôme Jouan, Emilie Varlet, Fabrice Vanhuyse, Hugues Blangy, Raphaël P Martins, Vincent Galand
发表日期
2019/8/1
期刊
American Heart Journal
卷号
214
页码范围
69-76
出版商
Mosby
简介
Background
Left ventricular assist device (LVAD)–associated infections may be life-threatening and impact patients' outcome. We aimed to identify the characteristics, risk factors, and prognosis of LVAD-associated infections.
Methods
Patients included in the ASSIST-ICD study (19 centers) were enrolled. The main outcome was the occurrence of LVAD-associated infection (driveline infection, pocket infection, or pump/cannula infection) during follow-up.
Results
Of the 652 patients enrolled, 201 (30.1%) presented a total of 248 LVAD infections diagnosed 6.5 months after implantation, including 171 (26.2%), 51 (7.8%), and 26 (4.0%) percutaneous driveline infection, pocket infection, or pump/cannula infection, respectively. Patients with infections were aged 58.7 years, and most received HeartMate II (82.1%) or HeartWare (13.4%). Most patients (62%) had implantable cardioverter-defibrillators (ICDs) before LVAD …
学术搜索中的文章
P Tattevin, E Flécher, V Auffret, C Leclercq, S Boulé… - American Heart Journal, 2019